Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Jubilant Cadista...

    Jubilant Cadista recalls 1.58 lakh bottles of erosive esophagitis tablets

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-10-21T11:01:29+05:30  |  Updated On 21 Oct 2018 11:01 AM IST
    Jubilant Cadista recalls 1.58 lakh bottles of erosive esophagitis tablets
    New Delhi: Jubilant Cadista Pharmaceuticals Inc, is recalling over 1.58 lakh bottles of Pantoprazole Sodium delayed-release tablets manufactured by Jubilant Generics Ltd at its Roorkee plant, from the America and Puerto Rico market, latest report of the US health regulator has said. The tablets are used for the treat gastroesophageal reflux disease(GERD).

    Jubilant Cadista Pharmaceuticals Inc is recalling 1,58,466 bottles of Pantoprazole Sodium delayed-release tablets USP in the strength of 40 mg, manufactured by Jubilant Generics Ltd, Roorkee, the Enforcement Report of the US Food and Drug Administration (USFDA) said.

    The reason for recall is "Discoloration: presence of dark discoloration or brown spots on the edges of the tablets," it added.

    The voluntary ongoing nationwide recall in the USA and Puerto Rico, is a class II recall, the report said.

    As per the USFDA, a class II recall is initiated in a situation, "in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."

    Read Also: Jubilant Cadista Pharma recalls over 46,000 bottles of hypertension drug from US
    Americaerosive esophagitis tabletsesophagitisgastroesophageal reflux diseaseJubilant Cadista PharmaceuticalsJubilant Generics LtdPantoprazolePantoprazole SodiumPuerto Rico marketRoorkee plantUS Food and Drug AdministrationUS health regulatorUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok